

As fatty liver disease prevalence soars, pharma companies look to first-in-class drugs

Écrit par GBI Research
Jeudi, 16 Mars 2017 20:35 -



Due to the increasing global prevalence of fatty liver disease (FLD), which comprises a spectrum of ch

The company's [latest report](#) states that FLD is the most common chronic liver disease in the w

Jennifer Goossens, Associate Analyst for GBI Research, explains: "Although FLD is increasingly recog

"Lifestyle changes and reduction of body weight are the primary recommendations to control FLD, whil

Due to the pathophysiological complexity of FLD and its diverse population, different therapeutic agent

Goossens continues: "The degree of first-in-class innovation is 15% above the industry average, which

"The majority of these products are small molecules in the early drug development stages. They also ta